Sign In
Buy ZYNE
$1.30
+0 (+0%)
At Close: Jan 09, 2024
Zynerba Pharmaceuticals Announces New Date for Reconvened Annual Meeting
05:18pm, Tuesday, 25'th Jul 2023
DEVON, Pa., July 25, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) (the “Company”), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for
Zynerba (ZYNE) Upgraded to Buy: What Does It Mean for the Stock?
01:39pm, Thursday, 29'th Jun 2023
Zynerba (ZYNE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zynerba Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
07:00am, Tuesday, 20'th Jun 2023
DEVON, Pa., June 20, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychia
Zynerba Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
07:00am, Tuesday, 07'th Mar 2023
DEVON, Pa, March 07, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychia
Zynerba Pharmaceuticals to Present at the Cowen 43rd Annual Health Care Conference
07:00am, Wednesday, 01'st Mar 2023
DEVON, Pa., March 01, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychi
Zynerba Pharmaceuticals Announces Publication in the Journal of Neurodevelopmental Disorders Describing the Role of the Endocannabinoid System and Cannabidiol Therapy in Fragile X Syndrome
01:30pm, Wednesday, 11'th Jan 2023 GlobeNewswire Inc.
Comprehensive data review suggests a central role for the endocannabinoid system (ECS) in neuronal development, cognitive function and in the pathogenesis of Fragile X syndrome (FXS)
Rising P/E: An Overlooked Way to Pick 5 Winning Stocks
12:19pm, Monday, 09'th Jan 2023 Zacks Investment Research
Want to try a different approach? Tap five stocks with increasing P/E ratios. These include CuriosityStream (CURI), Root (ROOT), LendingClub (LC), Manitex International (MNTX) and Zynerba Pharmaceutic
Rising P/E: An Overlooked Way to Pick 5 Winning Stocks
09:02am, Monday, 09'th Jan 2023
Want to try a different approach? Tap five stocks with increasing P/E ratios.
Zynerba Pharmaceuticals Announces Update on RECONNECT, the Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome
12:00pm, Wednesday, 21'st Dec 2022 GlobeNewswire Inc.
RECONNECT initial screening visits are being adversely impacted by environmental factors, such as the “Tripledemic” (high rates of RSV, influenza and COVID-19); topline results now expected first
Zynerba Pharmaceuticals revises timeline for release of topline results from Phase 3 RECONNECT trial of Zygel in Fragile X syndrome
07:46am, Wednesday, 21'st Dec 2022
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) has revised its timeline for releasing topline results from its multiple-centre Phase 3 RECONNECT trial, which sees Zygel administered to children and adolesc
Zynerba Pharmaceuticals Announces Positive Long-Term Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at the Annual Meeting of the American College of Neuropsychopharmacology
12:30pm, Monday, 05'th Dec 2022 GlobeNewswire Inc.
Zygel™ achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments and was generally well-tolerated through 38 weeks of treatment
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) said it has presented a poster at the 61st annual meeting of the American College of Neuropsychopharmacology, being held December 4-7, 2022 in Phoenix, Arizo
Zynerba Pharmaceuticals Announces Poster Presentation at the Annual Meeting of the American College of Neuropsychopharmacology
12:00pm, Tuesday, 29'th Nov 2022 GlobeNewswire Inc.
DEVON, Pa., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsych
Zynerba Pharmaceuticals Announces Publication of Data from Phase 3 CONNECT-FX Study of Zygel™ in the Journal of Neurodevelopmental Disorders
12:30pm, Monday, 28'th Nov 2022 GlobeNewswire Inc.
Study finds patients with Fragile X who have a highly methylated FMR1 gene that were treated with Zygel showed a significant reduction in behavioral symptoms compared to those treated with placebo
Zynerba Pharmaceuticals' Zygel shows meaningful behavioral symptom treatment progress in Fragile X patients in phase 3 trial
09:45am, Monday, 28'th Nov 2022
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) announced that Fragile X patients treated with Zygel showed a significant reduction in behavioral symptoms compared to those treated with a placebo in a recen
